
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is expected to continue to experience growth and success in its core immunology franchise, as well as in its recently acquired oncology and aesthetics portfolios. Strong volume growth is expected for key products, such as Rinvoq and Skyrizi, which are also projected to see favorable pricing dynamics. The company's pipeline, specifically in the neuroscience and oncology verticals, has the potential to add additional value to the company's overall portfolio. Risks include competition and pricing pressure, as well as potential delays or setbacks in the development of pipeline assets.
Bears say
AbbVie is facing numerous challenges that could negatively impact its stock performance. The company's key growth drivers, Skyrizi and Rinvoq, are facing strong competition in the immunology space and are expected to see slower growth than previously anticipated. Additionally, the increasing pricing pressure in the oncology segment, specifically on Imbruvica, is expected to continue, which could further impact AbbVie's bottom line. Despite efforts to diversify its portfolio through acquisitions, uncertainties remain around the success of these deals, such as Abivax's potential safety and labeling concerns and the delayed resubmission of TrenibotE for regulatory approval. Overall, the company's near-term financial outlook looks less promising, with a potential downside of 14% from its current stock price.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares